

**AMENDMENTS TO THE SPECIFICATION:**

Please replace the paragraph [0088] on page 25 with the following rewritten paragraph:

[0088] Further exemplary adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59™ (W090/14837; Chapter 10 in *Vaccine design: the subunit and adjuvant approach*, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing MTP-PE) formulated into submicron particles using a microfluidizer, (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) ~~Ribi™~~ **RIBI™** adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components such as monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (~~Detox™~~ **DETOX™**); (2) saponin adjuvants, such as QS21 or ~~Stimulon™~~ **STIMULON™** (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes), which ISCOMs may be devoid of additional detergent *e.g.* WO00/07621; (3) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (4) cytokines, such as interleukins (*e.g.* IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/44636), *etc.*), interferons (*e.g.* gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), *etc.*; (5) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) *e.g.* GB-2220221, EP-A-0689454, optionally in the substantial absence of alum when used with pneumococcal saccharides *e.g.* WO00/56358; (6) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions *e.g.* EP-A-0835318, EP-A-0735898, EP-A-0761231; (7) oligonucleotides comprising CpG motifs [Krieg *Vaccine* 2000, 19, 618-622; Krieg *Curr opin Mol Ther* 2001 3:15-24; Roman *et al.*, *Nat. Med.*, 1997, 3, 849-854; Weiner *et al.*, *PNAS USA*, 1997, 94, 10833-10837; Davis *et al.*, *J. Immunol.*, 1998, 160, 870-876; Chu *et al.*, *J. Exp. Med.*, 1997, 186, 1623-1631; Lipford *et al.*, *Eur. J. Immunol.*, 1997, 27, 2340-2344; Moldoveanu *et al.*, *Vaccine*, 1988, 16, 1216-1224, Krieg *et al.*, *Nature*, 1995, 374, 546-549; Klinman *et al.*, *PNAS USA*, 1996, 93, 2879-2883; Ballas *et al.*, *J. Immunol.*, 1996, 157, 1840-1845; Cowdery *et al.*, *J. Immunol.*, 1996, 156, 4570-4575; Halpern *et al.*, *Cell Immunol.*, 1996, 167, 72-78; Yamamoto *et al.*, *Jpn. J. Cancer Res.*,

1988, 79, 866-873; Stacey *et al*, *J. Immunol.*, 1996, 157,2116-2122; Messina *et al*, *J. Immunol*, 1991, 147, 1759-1764; Yi *et al*, *J. Immunol*, 1996, 157,4918-4925; Yi *et al*, *J. Immunol*, 1996, 157, 5394-5402; Yi *et al*, *J. Immunol*, 1998, 160, 4755-4761; and Yi *et al*, *J. Immunol*, 1998, 160, 5898-5906; International patent applications WO96/02555, W098/16247, WO98/18810, WO98/40100, WO98/55495, WO98/37919 and WO98/52581] *i.e.* containing at least one CG dinucleotide, where the cytosine is unmethylated; (8) a polyoxyethylene ether or a polyoxyethylene ester *e.g.* WO99/52549; (9) a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol (WO01/21207) or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol (WO01/21152); (10) a saponin and an immunostimulatory oligonucleotide (*e.g.* a CpG oligonucleotide) (WO00/62800); (11) an immunostimulant and a particle of metal salt *e.g.* WO00/23105; (12) a saponin and an oil-in-water emulsion *e.g.* WO99/11241; (13) a saponin (*e.g.* QS21) + 3dMPL + IM2 (optionally + a sterol) *e.g.* WO98/57659; (14) other substances that act as immunostimulating agents to enhance the efficacy of the composition. Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), *etc*

Please replace the paragraph [00170] on page 53 with the following rewritten paragraph:

[00170] MV or OMV preparations were diluted in PBS and either mixed with an equal volume of complete Freund's adjuvant (CFA; Sigma Chemical Company, St. Louis, MO) or aluminum hydroxide (~~Alhydrogel~~ **ALHYDROGEL™** 1.3% from Superfos Biosector, Frederikssund, Denmark), or aluminum phosphate (~~Alhydrogel~~ **ALHYDROGEL™** that had been incubated with PBS buffer for at least 3 hrs). In some vaccine preparations, CpG nucleotides (5'-TCCATGACGTTCTGACGTT-3' (SEQ ID NO:1) Chiron Corp., Emeryville, CA) were added to the aluminum phosphate/antigen mixture to a final concentration of 100 µg/ml as a second adjuvant. Mice were immunized by the IP (CFA) or SC (aluminum phosphate, aluminum hydroxide) routes with 100 µl containing between 5 to 25 micrograms of total protein of the MV prepared from the meningococcal strain RM1090.